Abstract
The marine environment is proving to be a very rich source of unique compounds with significant activities against cancer of several types. Finding the sources of these new chemical entities has made it necessary for marine and medical scientists to find enterprising ways to collaborate in order to sample the great variety of intertidal, shallow and deep-water sea life. Recently these efforts resulted in a first generation of drugs from the sea undergoing clinical trials. These include PharmaMar compounds: Yondelis, Aplidin, kahalalide F, ES285 and Zalypsis. Two of these compounds, kahalalide F and ES285, have been isolated from the Indopacific mollusc Elysia rufescens and the North Atlantic mollusc Spisula polynyma, respectively.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Becerro MA, Paul VJ, Goetz G, Scheuer PJ (2001) Chemical defences of the sacoglossan mollusk Elysia rufescens and its host alga Briopsis sp. J Chem Ecol 27:2287–2299
Brown AP, Morrissey RL, Faircloth GT, Levine BS (2002) Preclinical toxicity of Kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat. Cancer Chemother Pharmacol 50:333–340
Ciruelos C, Trigo J, Pardo J, Paz-Ares L, Estaun N, Cuadra C, DomÃnguez M, MarÃn A, Jimeno JM, Izquierdo M (2002) A phase I clinical and pharmacokinetic study with Kahalalide F in patients with advanced solid tumours with a continuous weekly 1-hour iv infusion schedule. Eur J Cancer 38:33
Córdoba S, Zapata I, Romero J, de la Torre A, López-Martin JA, Vargas JA, Sánchez-Prieto R, Corbacho C, Regueiro CA, Magallón R (2003) In vitro chemosensitivity, cell cycle redistribution and apoptosis induction by Kahalalide F, a new marine compound in a panel of human tumoural cells. Eur J Cancer Suppl 1:S173
Cuadros R, Montejo de Garcini E, Wandosell F, Faircloth GT, Fernández-Sousa JM, Avila J (2000) The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. Cancer Lett 152:23–29
Gajate C, An F, Nieto-Miguel T, Mollinedo F (2005) Induction of apoptosis by the novel marine-derived antitumour agent ES-285 (spisulosine): cell cycle arrest, and mitochondrial and caspase involvement (in press)
<AQ. Please update Gajate et al. (2005).>
GarcÃa-Rocha M, Bonay P, Avila J (1996) The antitumoural compound Kahalalide F acts on cell lysosomes. Cancer Lett 99:43–50
Gómez SG, Bueren JA, Faircloth GT, Jimeno J, Albella B (2003) In vitro toxicity of three new antitumoural drugs (trabectedin, aplidin and kahalalide F) on hematopoietic progenitors and stem cells. Exp Hematol 31:1104–1111
Green BJ, Li W, Manhart JR, Fox TC, Summer EJ, Kennedy RA, Pierce SK, Rumpho ME (2000) Mollusc–algal chloroplast endosymbiosis. Photosynthesis, thylakoid protein maintenance, and chloroplast gene expression continue for many months in the absence of the algal nucleus. Plant Physiol 124:331–342
Hamann MT, Scheuer PJ (1993) Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp. J Am Chem Soc 115:5825–5826
Hamann MT, Otto CS, Scheuer PJ, Dunbar DC (1996) Kahalalides, bioactive depsipeptides from the sacoblassan mollusk Elysia rufescens and the green alga Bryopsis sp. J Org Chem 61:6594–6600
Janmaat ML, Kruyt FAE, Jimeno J, RodrÃguez JA, Giaccone G (2004) Kahalalide F induces caspase-independent cytotoxicity that correlates with HER2 and/or HER3 expression levels and is accompanied by down-regulation of AKT signaling. Proc AACR 95:5328
Lacal JC, RodrÃguez-González A, Alvarez-Miranda M (2004) Study of the mechanism of action of ES285. PharmaMar, Madrid
López-Maciá A, Jiménez JC, Royo M, Giralt E, Albericio F (2001) Synthesis and structural determination of Kahalalide F. J Am Chem Soc 123:11398–11401
Nuijen B, Bouma M, Talsma H, Manada C, Jimeno JM, López-Lazaro L, Bult A, Beijnen JH (2001) Development of a lyophilized, parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent Kahalalide F. Drug Dev Ind Pharm 27:767–780
Rinehart KL, Fregeau NL, Warwick RA (1998) US patent 6107520c
Salcedo M (2005) The marine antitumour compound ES 285 activates EGD receptors and PKC, and in parallel triggers an atypical cell death pathway (in press)
Salcedo M, Cuevas C, Sánchez-Puelles JM, Otero G, Sousa JM, Avila J, Wandosell F (2003) Proc Am Assoc Cancer Res 44:3649
Schellens JH, Rademaker JL, Horenblas S, Meinhardt W, Stukvis E, de Reijke TM, Jimeno JM, López-Lazaro L, López-MartÃn JA, Beijnen JH (2002) Phase I and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer. Proc ASCO 38:451
Sewell JM, Langdon SP, Smyth JF, Jodrell I, Guichard S (2004) Kahalalide F appears to promote necrotic cell death in hepatoma cell lines. Proc AACR 95:1509
Suárez J, Gonzalez L, Cuadrado A, Berciano M, Lafarga M, Muñoz A (2003) Kahalalide F, a new marine-derived compound induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2:863–872
Tartakoff AM (1983) Perturbations of vesicular traffic with the carboxylic ionophore monensin. Cell 32:1026–1028
Wosikowski K, Schuurhuis D, Johnson K (1997) Identification of Epidermal growth factor receptor and c-ErbB2 pathway inhibitors by correlation with gene expression patterns. J Nat Cancer Inst 89:1505–1515
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Faircloth, G., del Carmen Cuevas Marchante, M. (2006). Kahalalide F and ES285: Potent Anticancer Agents from Marine Molluscs. In: Cimino, G., Gavagnin, M. (eds) Molluscs. Progress in Molecular and Subcellular Biology, vol 43. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-30880-5_16
Download citation
DOI: https://doi.org/10.1007/978-3-540-30880-5_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-30879-9
Online ISBN: 978-3-540-30880-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)